1. Pink Sheet
  2. >>Agency Leadership

Prebunk: FDA Needs To Get Ahead Of Misinformation, But It Likely Can’t Drive The Effort

 
• By Sarah Karlin-Smith

New report offers a five-point plan for FDA to improve the public’s understanding of its role including pushing the agency to be more proactive in listening for, spotting, and addressing misconceptions before they escalate. But experts caution that this must be done carefully, or it could fuel more distrust.

FDA Commissioner Robert Califf
Commissioner Califf reacts to Reagan-Udall report on strategies to improve public's understanding of FDA • Source: Reagan-Udall Foundation online event

The US Food and Drug Administration needs to take a more proactive approach to communicating to counter the tide of misinformation consumers are exposed to, a new report commissioned by the agency instructs. However, FDA Commissioner Robert Califf and other experts cautioned that some of this work may need to be led by outside parties to ensure public buy in.

FDA “should be more proactive in listening, for, spotting and addressing misconceptions before they escalate,” the Reagan-Udall Foundation for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

Prasad 2.0 Brings New Instability Concerns, Questions About Changed Regulatory Philosophy

 
• By Sarah Karlin-Smith

Many agency stakeholders believe Vinay Prasad may be forced to change his regulatory approach at least somewhat after receiving a second chance to lead the US FDA's biologics center.

More Telework, More Staff, US FDA’s Tidmarsh Plans To Alleviate Workforce Challenges

 
• By Sarah Karlin-Smith

The new CDER director focused on plans to improve morale during an Aug. 8 townhall, but staff comments indicate that may be a challenge.

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 
• By Sarah Karlin-Smith

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

US FDA Requires Opioid Class Labeling Changes Despite Adcomm Advice

 
• By Kate Rawson

Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.

More from Pink Sheet

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 
• By Anabel Costa-Ferreira

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval

 
• By Jessica Merrill

Ultragenyx said talks with the FDA about a path forward after receiving a CRL for UX111 have been productive despite the recent upheaval at the agency.

Prasad 2.0 Brings New Instability Concerns, Questions About Changed Regulatory Philosophy

 
• By Sarah Karlin-Smith

Many agency stakeholders believe Vinay Prasad may be forced to change his regulatory approach at least somewhat after receiving a second chance to lead the US FDA's biologics center.